Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
AMGN 
Amgen Inc (AMGN)
Today’s top pick
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/07/2025: AMGN (3-star) is a STRONG-BUY. BUY since 26 days. Profits (15.30%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
AI Based Fundamental Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Analysis of Past Performance
Type Stock | Historic Profit 28.45% | Avg. Invested days 41 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 03/07/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 164.88B USD | Price to earnings Ratio 40.54 | 1Y Target Price 315.95 |
Price to earnings Ratio 40.54 | 1Y Target Price 315.95 | ||
Volume (30-day avg) 3210159 | Beta 0.52 | 52 Weeks Range 251.27 - 338.98 | Updated Date 04/1/2025 |
52 Weeks Range 251.27 - 338.98 | Updated Date 04/1/2025 | ||
Dividends yield (FY) 3.06% | Basic EPS (TTM) 7.57 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 12.24% | Operating Margin (TTM) 51.81% |
Management Effectiveness
Return on Assets (TTM) 6.4% | Return on Equity (TTM) 67.55% |
Valuation
Trailing PE 40.54 | Forward PE 14.84 | Enterprise Value 213004941105 | Price to Sales(TTM) 4.93 |
Enterprise Value 213004941105 | Price to Sales(TTM) 4.93 | ||
Enterprise Value to Revenue 6.37 | Enterprise Value to EBITDA 15.95 | Shares Outstanding 537204992 | Shares Floating 535679281 |
Shares Outstanding 537204992 | Shares Floating 535679281 | ||
Percent Insiders 0.21 | Percent Institutions 82.01 |
Analyst Ratings
Rating 3.59 | Target Price 319.35 | Buy 4 | Strong Buy 10 |
Buy 4 | Strong Buy 10 | ||
Hold 15 | Sell 1 | Strong Sell 2 | |
Strong Sell 2 |
Upturn AI SWOT
Amgen Inc
Company Overview
History and Background
Amgen Inc. was founded in 1980 as Applied Molecular Genetics. A significant milestone was the FDA approval of Epogen in 1989. It has evolved into a global biotechnology leader.
Core Business Areas
- General Medicine: Focuses on therapies for cardiovascular disease, bone health, and other general medical conditions.
- Oncology: Develops and markets therapies for various types of cancer.
- Inflammation: Focuses on therapies for inflammatory diseases.
- Hematology: Focuses on therapies for various blood diseases and disorders
Leadership and Structure
Robert A. Bradway is the Chairman and CEO. The company operates with a functional organizational structure, divided into research, development, and commercial operations.
Top Products and Market Share
Key Offerings
- Enbrel: A TNF blocker used to treat autoimmune diseases like rheumatoid arthritis. Faces competition from biosimilars. Revenue 2023: $6.4 billion. Competitors: AbbVie's Humira, Johnson & Johnson's Remicade.
- Prolia/Xgeva: Prolia treats osteoporosis; Xgeva prevents skeletal-related events in cancer. Revenue 2023: $4.1 billion. Competitors: Novartis's Reclast, Merck's Fosamax.
- Neulasta/Neupogen: Used to stimulate white blood cell production in cancer patients undergoing chemotherapy. Faces competition from biosimilars. Revenue 2023: $1.7 billion. Competitors: Sandoz's Zarxio, Mylan's Fulphila.
- Otezla: An oral treatment for psoriasis and psoriatic arthritis. Revenue 2023: $2.5 billion. Competitors: Celgene's (now Bristol Myers Squibb) Apremilast, Novartis's Cosentyx.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high R&D spending, complex regulatory pathways, and intense competition. Patent protection and biosimilar challenges are critical factors.
Positioning
Amgen is a leading biotechnology company with a strong portfolio of established products and a robust pipeline of innovative therapies. It has competitive advantages in manufacturing and commercialization.
Total Addressable Market (TAM)
The global pharmaceutical market is estimated to be worth over $1.4 trillion. Amgen addresses a significant portion of this market, including oncology, inflammation, bone health, and cardiovascular disease.
Upturn SWOT Analysis
Strengths
- Strong product portfolio
- Robust pipeline of new drugs
- Established manufacturing capabilities
- Strong financial performance
- Global presence
Weaknesses
- Reliance on key products
- Exposure to biosimilar competition
- High R&D expenses
- Patent expirations
Opportunities
- Expansion into new therapeutic areas
- Strategic acquisitions and partnerships
- Growth in emerging markets
- Development of innovative therapies
- Leveraging digital health technologies
Threats
- Increasing competition from biosimilars
- Pricing pressures and healthcare reforms
- Regulatory hurdles
- Patent challenges
- Economic downturns
Competitors and Market Share
Key Competitors
- JNJ
- MRK
- PFE
- ABBV
- BMY
Competitive Landscape
Amgen faces competition from established pharmaceutical companies and emerging biotechnology firms. Its strengths include its manufacturing capabilities and global presence. Its weaknesses include its reliance on key products and exposure to biosimilar competition.
Major Acquisitions
Horizon Therapeutics
- Year: 2023
- Acquisition Price (USD millions): 27800
- Strategic Rationale: Expands Amgen's portfolio in rare diseases and inflammation.
Growth Trajectory and Initiatives
Historical Growth: Amgen has experienced consistent revenue and earnings growth over the past decade, driven by its strong product portfolio and strategic acquisitions.
Future Projections: Analysts project continued revenue and earnings growth for Amgen in the coming years, driven by its pipeline and strategic initiatives.
Recent Initiatives: Recent initiatives include acquisitions of Horizon Therapeutics, investments in new manufacturing facilities, and development of innovative therapies.
Summary
Amgen is a strong biotechnology company with a diverse product portfolio and a robust pipeline. Its established manufacturing capabilities and global presence are significant advantages. However, Amgen faces challenges from biosimilar competition and pricing pressures and must continue to innovate and pursue strategic acquisitions to drive future growth.
Similar Companies
ABBV
AbbVie Inc
ABBV
AbbVie Inc
BMY
Bristol-Myers Squibb Company
BMY
Bristol-Myers Squibb Company
GILD
Gilead Sciences Inc
GILD
Gilead Sciences Inc
JNJ
Johnson & Johnson
JNJ
Johnson & Johnson
LLY
Eli Lilly and Company
LLY
Eli Lilly and Company
MRK
Merck & Company Inc
MRK
Merck & Company Inc
PFE
Pfizer Inc
PFE
Pfizer Inc
Sources and Disclaimers
Data Sources:
- Amgen Investor Relations
- SEC Filings
- Analyst Reports
- Company Press Releases
- Third Party Market Research
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Amgen Inc
Exchange NASDAQ | Headquaters Thousand Oaks, CA, United States | ||
IPO Launch date 1983-06-17 | Chairman, CEO & President Mr. Robert A. Bradway | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 28000 | Website https://www.amgen.com |
Full time employees 28000 | Website https://www.amgen.com | ||
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.